Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Moleculin Biotech (NASDAQ: MBRX) has announced that its research on Annamycin, their next-generation anthracycline drug candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The presentation, scheduled for April 28, 2025, will focus on combining Annamycin with various other drugs to enhance anticancer effects.
The poster presentation, titled 'Combining Annamycin, a Non-cardiotoxic Potent Topo II Poison, with Azacitidine, Cytarabine, Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to Synergize Anticancer Effects and Identify Potential Clinical Applications' will be delivered by Dr. Rafal Zielinski from MD Anderson Cancer Center. The presentation is part of the Drug Combination Strategies for Cancer Treatment session.
Moleculin Biotech (NASDAQ: MBRX) ha annunciato che la sua ricerca su Annamycin, il loro candidato farmaco di nuova generazione appartenente alla classe delle antracicline, sarà presentata al Meeting Annuale 2025 dell'American Association for Cancer Research (AACR). La presentazione, prevista per il 28 aprile 2025, si concentrerà sulla combinazione di Annamycin con diversi altri farmaci per potenziare gli effetti anticancro.
Il poster, intitolato 'Combinazione di Annamycin, un potente inibitore di Topo II non cardiotossico, con Azacitidina, Citarabina, Gemcitabina, Ifosfamide, Trabectedina o Vincristina per sinergizzare gli effetti anticancro e identificare potenziali applicazioni cliniche', sarà presentato dal Dr. Rafal Zielinski del MD Anderson Cancer Center. La presentazione fa parte della sessione Strategie di combinazione farmacologica per il trattamento del cancro.
Moleculin Biotech (NASDAQ: MBRX) ha anunciado que su investigación sobre Annamycin, su candidato a fármaco de próxima generación de antraciclina, será presentada en la Reunión Anual 2025 de la Asociación Americana para la Investigación del Cáncer (AACR). La presentación, programada para el 28 de abril de 2025, se centrará en la combinación de Annamycin con varios otros medicamentos para potenciar los efectos anticancerígenos.
La presentación en póster, titulada 'Combinando Annamycin, un potente veneno de Topo II no cardiotóxico, con Azacitidina, Citarabina, Gemcitabina, Ifosfamida, Trabectedina o Vincristina para sinergizar efectos anticancerígenos e identificar posibles aplicaciones clínicas', será realizada por el Dr. Rafal Zielinski del MD Anderson Cancer Center. La presentación forma parte de la sesión Estrategias de combinación de fármacos para el tratamiento del cáncer.
Moleculin Biotech (NASDAQ: MBRX)는 차세대 안트라사이클린 약물 후보인 Annamycin에 대한 연구를 2025년 미국 암 연구 협회(AACR) 연례 회의에서 발표할 예정이라고 밝혔습니다. 2025년 4월 28일에 예정된 이번 발표는 Annamycin을 다양한 다른 약물과 결합하여 항암 효과를 강화하는 데 중점을 둘 것입니다.
'심장 독성이 없는 강력한 토포이소머라제 II 억제제 Annamycin을 아자시티딘, 시타라빈, 젬시타빈, 이포스파미드, 트라베크테딘 또는 빈크리스틴과 결합하여 항암 효과를 상승시키고 잠재적 임상 적용을 식별하기'라는 제목의 포스터 발표는 MD 앤더슨 암 센터의 라팔 지엘린스키 박사가 진행합니다. 이 발표는 암 치료를 위한 약물 병용 전략 세션의 일부입니다.
Moleculin Biotech (NASDAQ : MBRX) a annoncé que ses recherches sur Annamycin, leur candidat médicament anthracycline de nouvelle génération, seront présentées lors de la Réunion Annuelle 2025 de l'American Association for Cancer Research (AACR). La présentation, prévue pour le 28 avril 2025, portera sur la combinaison d'Annamycin avec divers autres médicaments afin de renforcer les effets anticancéreux.
La présentation sous forme de poster, intitulée « Combinaison d'Annamycin, un puissant poison de Topo II non cardiotoxique, avec Azacitidine, Cytarabine, Gemcitabine, Ifosfamide, Trabectédine ou Vincristine pour potentialiser les effets anticancéreux et identifier des applications cliniques potentielles », sera présentée par le Dr Rafal Zielinski du MD Anderson Cancer Center. Cette présentation fait partie de la session Stratégies de combinaisons médicamenteuses pour le traitement du cancer.
Moleculin Biotech (NASDAQ: MBRX) hat angekündigt, dass ihre Forschung zu Annamycin, ihrem Anthrazyklin-Wirkstoffkandidaten der nächsten Generation, auf dem Jahrestreffen 2025 der American Association for Cancer Research (AACR) vorgestellt wird. Die Präsentation, die für den 28. April 2025 geplant ist, konzentriert sich auf die Kombination von Annamycin mit verschiedenen anderen Medikamenten zur Verstärkung der krebsbekämpfenden Wirkung.
Die Posterpräsentation mit dem Titel „Kombination von Annamycin, einem nicht kardiotoxischen starken Topo-II-Gift, mit Azacitidin, Cytarabin, Gemcitabin, Ifosfamid, Trabectedin oder Vincristin zur Synergierung der anticancerogenen Effekte und Identifizierung potenzieller klinischer Anwendungen“ wird von Dr. Rafal Zielinski vom MD Anderson Cancer Center gehalten. Die Präsentation ist Teil der Sitzung „Strategien zur Kombination von Medikamenten bei der Krebsbehandlung“.
- None.
- None.
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company’s next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.
Details of the presentation are as follows:
Title: Combining Annamycin, a Non-cardiotoxic Potent Topo II Poison, with Azacitidine, Cytarabine, Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to Synergize Anticancer Effects and Identify Potential Clinical Applications
Track: Experimental and Molecular Therapeutics
Session: PO.ET02.03. Drug Combination Strategies for Cancer Treatment
Abstract Number: 1683/ 14
Presenter: Rafal Zielinski, Ph.D., Department of Experimental Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center
Date and Time: April 28, 2025, 9:00 AM – 12:00 PM ET
Location: Section 19
For more information and to view the abstract, visit the AACR Annual Meeting website.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the achievements of each of the milestones in this press release. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
FAQ
What will be presented about MBRX's Annamycin at AACR 2025?
Who is presenting Moleculin's (MBRX) research at AACR 2025?
What are the key features of MBRX's Annamycin drug candidate?
When and where will MBRX's Annamycin research be presented at AACR 2025?
